Clinical Trials Browser

Phase 1/2 × INDUSTRY × apalutamide × Clear all

NCT01171898 2026-02-24

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms